119 related articles for article (PubMed ID: 33883484)
1. Efficacy and Safety of the 64Cu(II)Cl2 PET/CT for Urological Malignancies: Phase IIa Clinical Study.
Mascia M; Villano C; De Francesco V; Schips L; Marchioni M; Cindolo L
Clin Nucl Med; 2021 Jun; 46(6):443-448. PubMed ID: 33883484
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
4. Phase I/IIa PET imaging study with
Joraku A; Hatano K; Kawai K; Kandori S; Kojima T; Fukumitsu N; Isobe T; Mori Y; Sakata M; Hara T; Nasu K; Minami M; Iizumi Y; Nishiyama H
Ann Nucl Med; 2019 Feb; 33(2):119-127. PubMed ID: 30406361
[TBL] [Abstract][Full Text] [Related]
5. PET Using a GRPR Antagonist
Zhang J; Niu G; Fan X; Lang L; Hou G; Chen L; Wu H; Zhu Z; Li F; Chen X
J Nucl Med; 2018 Jun; 59(6):922-928. PubMed ID: 29123014
[TBL] [Abstract][Full Text] [Related]
6. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
7. Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting
Suh M; Ryoo HG; Kang KW; Jeong JM; Jeong CW; Kwak C; Cheon GJ
Korean J Radiol; 2022 Sep; 23(9):911-920. PubMed ID: 35762185
[TBL] [Abstract][Full Text] [Related]
8. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy of
Cantiello F; Gangemi V; Cascini GL; Calabria F; Moschini M; Ferro M; Musi G; Butticè S; Salonia A; Briganti A; Damiano R
Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628
[TBL] [Abstract][Full Text] [Related]
10. Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for
Uprimny C; Bayerschmidt S; Kroiss AS; Fritz J; Nilica B; Svirydenka H; Decristoforo C; von Guggenberg E; Horninger W; Virgolini IJ
J Nucl Med; 2021 Nov; 62(11):1550-1557. PubMed ID: 33712533
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of PET/CT with carbon-11 4DST in the evaluation of malignant and benign lung tumors.
Nishii R; Saga T; Sudo H; Togawa T; Kuyama J; Tani T; Maeda T; Kobayashi M; Iizasa T; Shingyoji M; Itami M; Kawamura K; Hashimoto H; Yamazaki K; Tamura K; Higashi T
Ann Nucl Med; 2021 Feb; 35(2):211-222. PubMed ID: 33387282
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms.
Long T; Yang N; Zhou M; Chen D; Li Y; Li J; Tang Y; Liu Z; Li Z; Hu S
Clin Nucl Med; 2019 Jun; 44(6):452-458. PubMed ID: 30985413
[TBL] [Abstract][Full Text] [Related]
14.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
15. Early dynamic imaging in
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; Warwitz B; Scarpa L; Roig LG; Kendler D; von Guggenberg E; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):765-775. PubMed ID: 27900519
[TBL] [Abstract][Full Text] [Related]
16. Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.
Domachevsky L; Goldberg N; Bernstine H; Nidam M; Groshar D
Eur Radiol; 2018 Dec; 28(12):5275-5283. PubMed ID: 29846803
[TBL] [Abstract][Full Text] [Related]
17. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
19. [
Zanoni L; Bianchi L; Nanni C; Pultrone C; Giunchi F; Bossert I; Matti A; Schiavina R; Fiorentino M; Romagnoli D; Fonti C; Lodi F; D'Errico A; Brunocilla E; Porreca A; Fanti S
Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):390-409. PubMed ID: 34213609
[TBL] [Abstract][Full Text] [Related]
20. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]